)
)
)
InterAct Therapeutics (IAT) is a preclinical company advancing its proprietary InterAct Print™ platform to deliver transformative gene therapies for metastatic cancers. Our lead candidate, IAT-S2, targets breast cancer-derived liver metastases (BCLM), a devastating orphan disease with no approved therapy and a 5-year survival rate below 10%. IAT-S2 introduces a transgene to hepatocytes, reprogramming the liver microenvironment to inhibit metastatic tumor growth. We are about 18 months from IND submission. We recently submitted to the FDA our INTERACT Meeting package and Orphan Drug Designation application. InterAct Print™ is a proprietary computational biology engine that identifies the genes most essential for metastatic colonization across different organs. Once validated in BCLM, it provides a repeatable framework to rapidly expand into other metastasis-dominant and oligometastatic indications. We have additional drug candidates in our pipeline.
Year Founded
2025
Next catalyst (value inflection) update
We have several in vivo efficacy studies about to read out. We will soon commence a minipig toxicology study abd manufacturing for our First-in-Human clinical trial.
Expected time of next catalyst update
March 2026.
City
Dallas
Country
United States
Company CEO or top company official
Daniel Hargrove, JD, LLM
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
IAT-S2 is a first-in-class therapeutic candidate designed to disrupt the fundamental biological mechanisms of liver colonization and metastatic spread. While most oncology therapies target the primary tumor or established metastases, IAT-S2 specifically intervenes in the "pre-metastatic niche"—addressing the critical phase where infiltrating tumor cells "create space" in distant organs to establish new colonies. Platform-Derived Discovery: Identified via the proprietary InterAct Print™ computational engine, which decoded the specific genetic drivers and signaling pathways required for successful tumor-to-organ colonization. Novel Modality: As a gene therapy/immunotherapy hybrid, IAT-S2 targets the essential genes that facilitate the survival and expansion of metastatic seeds, particularly in high-incidence sites like the liver. High Unmet Need: By targeting the colonization process itself, IAT-S2 offers a unique path to curative intent in patients with high metastatic risk, a segment where traditional checkpoint inhibitors and systemic therapies frequently fail.
Number of Unlicensed Products
2
Therapeutic Area
Oncology
Website
https://www.interacttx.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
